ID   AGS-5FU-R
AC   CVCL_B7H2
SY   AGS-R
DR   cancercelllines; CVCL_B7H2
DR   Wikidata; Q112929199
RX   DOI=10.21203/rs.3.rs-1302156/v1;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Stomach; UBERON=UBERON_0000945.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0139 ! AGS
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   DOI=10.21203/rs.3.rs-1302156/v1;
RA   Chang H.J., Cho M.-H., Choi M.Y., Lee K.E.;
RT   "Establishment of a 5-fluorouracil-resistant human gastric cancer cell
RT   line and exploration of its biological characteristics.";
RL   Res. Sq. 2022:1302156-1302156(2022).
//